BioCentury Podcasts

•

Canale • 2 podcast

Scienze biologiche

Scienze biologiche

Ogni 2 settimane
Scienze biologiche

Scienze biologiche

Ogni settimana

21/05/2025

Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva

As CEO of a vintage 2021 biotech, Jorge Santos Da Silva has had his leadership mettle tested by a pandemic, rising interest rates, a bear market, and a tumultuous U.S. policy environment — all while building the case for Moonlake’s lead program to become a top therapy for hidradenitis suppurativa and, eventually, a “pipeline-in-a-product.” The key for Santos Da Silva as founder and CEO of Moonlake Immunotherapeutics is to dial down the noise and focus on the key choices in front of you. “Moonlake has always existed in times of turmoil,” Santos Da Silva told Executive Editor Jeff Cranmer on The BioCentury Show, citing the recent M&A drought, high interest rates and political turmoil. “Understanding the situation from a cool perspective, being able to explain that to your people first, and then try to explain that to the Street and place the company in the right moment so that you have all the game in front of you" is his recipe for success as a CEO in biotech. Moonlake’s sonelokimab is expected to enter Phase III testing this year for HS; it's one of the most advanced multispecifics in the clinic for inflammation and immunology diseases. View full story: https://www.biocentury.com/article/655903 #biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment 00:00 - Introduction 01:48 - Landscape for HS Therapies 09:03 - Market Opportunity 19:40 - Next Steps for Moonlake

21/05/2025

•

29 min
15/02/2025

Ep. 279 - East-West Summit Preview

Western VCs are paying more attention than ever to innovation emerging from Asia — from antibody-drug conjugates to bispecifics, AI and beyond — as the NewCo Model becomes the latest trend to bridge talent, assets and venture money across the Pacific and on to North America and Europe. On a special edition of BioCentury This Week podcast, a trio of leaders from Asia’s life sciences ecosystem — Khoo Shih of Singaporean investor ClavystBio, McKinsey & Company’s Anirudh Roy Popli and Wendy Pan of Goodwin and BayHelix — join the BioCentury team to set the stage for the fourth BioCentury-BayHelix East-West Biopharma Summit. They discuss the innovations driving the deal flow from East to West, including the creation of start-ups in the West formed around assets from Asia. The summit takes place March 3-5 in Singapore. View full story: https://www.biocentury.com/article/655108 00:00 - Introduction 04:49 - The Newco Model and Industry Trends 09:13 - BayHelix and Cross-Border Transactions 11:31 - McKinsey's Perspective on Asian Innovation 26:58 - Final Thoughts and Registration Information To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

15/02/2025

•

30 min
08/03/2025

Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery

Since the annual J.P. Morgan Healthcare Conference in San Francisco in early January, biotech has seen a notable surge in enthusiasm, Zahid Moneer, senior managing director of investment banking at BNP Paribas, told The BioCentury Show. Moneer, who is more upbeat than many in today’s biopharma sector, sees capital raises from million-dollar seed rounds to nine-digit series A, B, and C rounds driving significant growth alongside M&A activity. In the interview, he also also highlights the growing role of private equity firms in biopharma and the trend of pharmas engaging earlier with biotechs and investors looking to deploy capital into those companies View full story: https://www.biocentury.com/article/655216 #biotech #biopharma #pharma #lifescience #financing #privateequity #IPO 00:00 - Introduction 00:37 - Investment Climate 05:06 - Pharma M&A Activity 15:25 - Private Equity's Role 21:44 - Biotech Financing

08/03/2025

•

30 min
04/03/2025

Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity

The track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform companies should validate their technology on established targets or pursue new ones. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the lessons learned by this small group of companies since their launch a decade ago. They also discuss the entrance of AbbVie into the obesity race via a $350 million deal with Gubra for a clinical stage amylin agonist — does it signal AbbVie’s belief in amylin monotherapy, or will the company be hunting for more obesity assets? The editors also talk about recommendations to streamline the early-stage development of rare disease therapies in the U.S. View full story: https://www.biocentury.com/article/655214 00:00 - Introduction 00:36 - CRISPR Companies 09:22 - AbbVie Enters Obesity Race 17:19 - Rare Disease Drug Challenges To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

04/03/2025

•

24 min
25/02/2025

Ep. 281 - Roche Reboot and 5 Things on Trump 2.0

Once pharma’s oncology powerhouse, Roche is charting a new course that extends beyond its traditional stronghold in cancer therapeutics. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how the Swiss pharma has reshaped its strategy for long-term growth. They also discuss another tumultuous weekend for staff at FDA and NIH, as well as the challenges of precision medicine for psychiatric conditions. View full story: https://www.biocentury.com/article/655157 00:00 - Introduction 00:45 - Roche Reboot 08:47 - Precision Medicine in Psychiatry 13:07 - 5 Things on Trump 2.0 To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

25/02/2025

•

22 min
17/01/2025

Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds

Sunshine and a stream of deals brightened the mood at this year’s J.P. Morgan Healthcare Conference, offering a pleasant counterpoint to continued pessimism over the state of the capital markets. On the latest BioCentury This Week podcast, BioCentury’s editors deliver their takeaways from biotech’s annual kick-off event from megarounds and Asian newcos to the new state of M&A and pending change at FDA. View full story: https://www.biocentury.com/article/654723 00:00 - Introduction 01:52 - Market Sentiments and Deal Expectations 04:42 - Cross-Border Deals and Asia's Growing Influence 07:12 - Neurology and Innovation in Biotech 14:44 - VC Trends and Megarounds 20:00 - Upcoming East West Singapore To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

17/01/2025

•

22 min
10/01/2025

Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A

Specialist public investors are doing their best to hold up the sector, but biotech still has to wash out many of the lower quality companies that were funded during the boom and ended up driving the generalists away, said MPM Bioimpact's Chris Bardon on The BioCentury Show. Bardon said the market hasn’t yet found the footing that will see an opening of the IPO window and a swing of positive sentiment. But although markets aren’t yet out of the woods, she said M&A will remain robust for years, fueled by obesity drug revenues. View full story: https://www.biocentury.com/article/654649 #biotech #biopharma #pharma #lifescience #financing #investing 00:00 - Introduction 01:30 - Market Sentiment 06:19 - IPO Window 12:04 - M&A Outlook 19:51 - The Obesity Landscape

10/01/2025

•

34 min
20/08/2024

Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School

The Biden administration has disclosed what Medicare will pay for the first graduates of its drug price negotiation program but biopharma companies, biotech investors and patient advocates are still waiting for the government to reveal how those prices were determined — details that are critical to informing the decisions that will shape the future of medicine. On the latest BioCentury This Week podcast, BioCentury’s editors discuss what last week’s disclosure tells us — and what information is yet to come. They also discuss why psychedelics companies believe they can avoid the hurdles that tripped up Lykos Therapeutics as it sought approval of its MDMA program to treat post-traumatic stress disorder (PTSD), and preview this year’s BioCentury Back to School report, which focuses on whether biotech can write a more successful playbook for translating from target to product. Take part in BioCentury’s Snap Survey on the IRA and Part D pricing. We’ll be publishing the results next week, which means we need your input now! All results will be anonymous. View full story: https://www.biocentury.com/article/653298 00:00 - Intro 01:32 - Medicare Drug Pricing 11:38 - Psychedelic Setback 18:53 - Back to School Preview Reach us by sending a text

20/08/2024

•

26 min
13/01/2025

Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma

J&J’s $14.6 billion takeout of neurology play Intra-cellular Therapies headlined a buzzy start to the J.P. Morgan Healthcare Conference, where a flurry of deal announcements recalled the conference’s pre-pandemic days. On the latest BioCentury This Week podcast, BioCentury's editors discuss the takeout of Intra-cellular, the third 11-digit neuro M&A in the past 13 months, as well as M&A involving Idrx and GSK, and Scorpion Therapeutics and Eli Lilly. Turning to Washington, the team explores what’s behind BIO CEO John Crowley’s visit to Mar-a-Lago to meet with President-elect Donald Trump, impending changes at FDA under Trump 2.0 and key takeaways from Rep. Jake Auchincloss appearance on BCTW’s sister podcast, The BioCentury Show. The team also breaks down the key trends in the past year in FDA approvals. This episode of BioCentury This Week was sponsored by ICON Biotech. View full story: https://www.biocentury.com/article/654694 00:01 - Sponsor Message: ICON Biotech 02:38 - JPM Deal Buzz 11:20 - Washington Update 16:08 - Rep. Auchincloss’ Take on Biopharma 21:01 - FDA Regulatory Decisions To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

13/01/2025

•

27 min
12/06/2025

Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago

With federal funding at risk and VCs increasingly focused on de-risked assets, academia is facing unprecedented headwinds despite rapid advancements in innovation. One potential bright spot: Pharma, which is turning to academia to access first-in-class innovation. But many in pharma complain it is difficult to work with academia. On a special Grand Rounds edition of the BioCentury This Week podcast, BioCentury analysts and special guests discuss a new way of thinking and a new era of collaboration between academia and industry. View full story: https://www.biocentury.com/article/656177 #biotech #biopharma #pharma #lifescience #Discovery #Translation #BioCenturyGrandRounds 00:00 - Introduction 02:38 - Key Findings 07:42 - Collaboration and Opportunities 25:52 - BioCentury Grand Rounds Europe To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

12/06/2025

•

31 min

BioCentury Podcasts leverage three decades of biopharma intelligence with thoughtful, accurate, and objective insights. BioCentury editors spotlight key scientific opinion leaders, corporate decision-makers, venture capitalists, and patient advocates, keeping you informed on the most current biotech stories and highlighting life science innovations.

Sito web

BioCentury Podcasts

Top podcast

Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva

Ep. 279 - East-West Summit Preview

Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery

Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity

Ep. 281 - Roche Reboot and 5 Things on Trump 2.0

Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds

Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A

Ep. 247 - Drug Pricing, Psychedelic Setback & Back to School

Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma

Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago

Descrizione

BioCentury Podcasts

Top podcast

Top puntate

Descrizione